EyePoint at Guggenheim conference: DME becomes the main focus
On 09 November 2026, at the 3rd Annual Guggenheim Healthcare Innovation Conference, EyePoint Pharmaceuticals Inc. (EYPT) discussed a shift in focus from wet age-related macular degeneration (AMD) to diabetic macular edema (DME). The company's stock had plummeted 98% year-to-date, trading at $0.36 and boasting a market capitalization of $30.78 million. CEO Jay Duker and CFO George emphasized their focus on DME, where they believe DURAVYU's mechanism of action fits the disease better and the market is larger.
The wet AMD Phase III trials, LUGANO and LUCIA, failed to meet their primary endpoint of non-inferiority in visual acuity versus 2mg EYLEA. However, DURAVYU demonstrated strong safety data and meaningful secondary benefits, such as better fluid control and fewer injections. The company expects data from two Phase III DME trials, COMO and CAPRI, in very early Q4 2025.
These trials include 550 patients, with a 75% treatment-naive and 25% previously treated mix. Management expressed confidence in DME, citing faster and more durable results from DURAVYU compared to wet AMD.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
